SynAct Pharma AB (publ) (“SynAct”) today announced that CEO Torbjørn Bjerke will present at the upcoming 2023 BIO International Convention on June 6, 2023, in Boston, Massachusetts. Bjerke will speak to senior biotech executives, business development leaders and investors about SynAct’s lead asset AP1189 and resolution of inflammation through the selective activation of the melanocortin system.
“Being selected to present at BIO is in part validation of the hard work we have done to advance our once-daily oral AP1189 program in rheumatoid arthritis,” said SynAct Pharma’s CEO Torbjørn Bjerke. “SynAct is at an incredible inflection point with clinical study data from both the EXPAND and RESOLVE RA studies due in the second half of this year. AP1189 and the selective melanocortin receptor agonists that we acquired earlier this year could help usher in a new way to approach chronic inflammatory diseases with resolution therapy, modulating instead of suppressing the immune system.”
The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering and brings together thousands of global biotechnology, and biopharmaceutical leaders. The four-day, in-person event includes networking, programming and partnering opportunities.
The information was submitted, through the agency of the contact person below, for publication on May 31, 2023, at 08:00 CEST.
For further information, please contact:
Torbjørn Bjerke, MD
CEO, SynAct Pharma AB
Phone: +46 727 44 41 58
Mail: [email protected]
Mail: [email protected]